News
Abstracts & Publications
Platelet Response to Increased Aspirin Dose in Patients Whose Platelets were Non-Responsive to Lower Aspirin Doses (Encore)
Dec 05, 2011
F. Gengo; M.Rainka; E. Westphal; M. Robson; M. Hourihane; V. Bates
The Journal of Clinical Pharmacology; September 2010 :
The most common aspirin dose for secondary stroke prophylaxis is 81 mg daily though current FDA guidelines suggest doses between 50...
Treatment Options for Multiple Sclerosis: Current and Emerging Therapies
Dec 05, 2011
KM. Gawronski; MM Rainka; MJ Patel; FM. Gengo
Pharmacotherapy; Volume 30, Issue 9; September 2010 :
Multiple sclerosis is a chronic autoimmune disease affecting the central nervous system, more specifically, the myelin sheath covering of nerve fibers in the brain...
Neuroimaging in Neuro-Oncology
Dec 05, 2011
Laszlo Mechtler, MD
Neurologic Clinics; Volume 27, Number 1; February 2009 :
The introduction of MRI into clinical practice has been among the most important of all advances in the care of patients with brain tumors. Neuroimaging is no longer a...
Attenuation of Risperidone-Induced Hyperprolactinemia with the Addition of Aripiprazole
Dec 05, 2011
Rainka, MM; Capote, HA; Ross, CA; Gengo, FM
Journal of Clinical Pharmacy and Therapeutics. Volume 24, Issue 5; October 2009 :
Hyperprolactinemia can be a complication of conventional neurolepics as well as risperidone. We report the third case of attenuation...
Neuroimaging of Headaches
Dec 05, 2011
Laszlo L. Mechtler, MD
Continuum Lifelong Learning in Neurology; Volume 14, Number 4; August 2008 :
Imaging for headaches is one of the most frequent and at times challenging decisions a neurologist has to make in the clinical practice of...
The Prevalence of Platelet Nonresponsiveness to Aspirin-Patients Treated for Secondary Stoke Prophylaxis & Patients with Recurrent Ischemic Events
Dec 05, 2011
F. Gengo, M. Rainka, M. Robson, M. Gengo, A. Forrest, M. Hourihane, V. Bates
Journal of Clinical Pharmacology. Volume 48, Number 3; Jan 2008 :
To determine the prevalence of platelet nonresponsiveness to aspirin treatment for secondary stroke prophylaxis, the...
Population Pharmacodynamic Modelling of Aspirin & Ibuprofen
Dec 05, 2011
V. Hong, F. Gengo, M. Rainka, V. Bates, D. MagerClinical Pharmacokinetics; Volume 47, Number 2; 2008 :
The objective of this study was to develop a mechanism-based pharmacodynamic model that characterizes the antiplatelet effects of aspirin (acetylsalicylic acid)...
Effects of Ibuprofen on Magnitude & Duration of Aspirin
Dec 05, 2011
F. Gengo, L. Rubin, M. Robson, M. Rainka, M. Gengo, D. Mager, V. BatesJournal of Clinical Pharmacology; Volume 48, Number 1; Jan 2008 :
This study was designed to measure the magnitude and duration of inhibition of platelet...
